Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Správa z výročnej konferencie ASCO® 2019 – gynekologické malignity
18 septembra, 2020 8:00 pmPočas prvého júnového týždňa tohto roku sa konal v Chicagu tradičný výročný kongres Americkej onkologickej spoločnosti (ASCO®). Tento rok bolo vybratých...
Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study
18 septembra, 2020 8:00 pmAuthors: Sara A. Hurvitz, Miguel Martin, Kyung Hae Jung, et. al. Abstract: 500 Clinical Trial Registry Number: NCT02131064...
Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant Tamoxifen – To offer more? (aTTom) trial
18 septembra, 2020 8:00 pmAuthors: John Bartlett, Dennis Sgroi, Kai Treuner, et. al. Abstract: 505 Citation: J Clin Oncol 37, 2019 (suppl;...
Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results
18 septembra, 2020 8:00 pmAuthors: Sara A. Hurvitz, Seock-Ah Im, Yen-Shen Lu, et. al. Abstract: LBA1008 Clinical Trial Registry Number: NCT02278120 ...
IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC)
18 septembra, 2020 8:00 pmAuthors: Peter Schmid, Sylvia Adams, Hope S. Rugo, et. al. Abstract: 1003 Clinical Trial Registry Number: NCT02425891 ...
Adding Ribociclib to First-Line Endocrine Therapy Significantly Improves Survival for Pre-Menopausal Women with Advanced Breast Cancer
18 septembra, 2020 8:00 pmJune 1, 2019 Adding Ribociclib to First-Line Endocrine Therapy Significantly Improves Survival for Pre-Menopausal Women with Advanced Breast Cancer...
VÝROČNÁ KONFERENCIA ASCO® 2019 Vybrané referáty – karcinóm prsníka
18 septembra, 2020 8:00 pmTohtoročná výročná konferencia ASCO® nepriniesla na poli liečby a diagnostiky karcinómu prsníka žiadnu prelomovú správu. Napriek tomu sa dá toto významné...
RATIFY: PROGNOSTIC IMPACT OF FLT3 TYROSINE KINASE DOMAIN (TKD) AND NPM1 MUTATION STATUS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) TREATED WITH MIDOSTAURIN + STANDARD CHEMOTHERAPY
15 septembra, 2020 7:11 pmAuthor(s): Maria Teresa Voso, Richard A. Larson, Thomas Prior, et. al. EHA Library. Voso M. Jun 14, 2019; 266056; PF256...
RESULTS OF ASTRAL-1 STUDY, A PHASE III RANDOMIZED TRIAL OF GUADECITABINE (G) VS TREATMENT CHOICE (TC) IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN-AML) NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY (IC)
15 septembra, 2020 7:11 pmAuthor(s): Pierre Fenaux, Marco Gobbi, Patricia L. Kropf, et. al. EHA Library. Fenaux P. Jun 15, 2019; 267462; S879 ...
A PHASE II STUDY OF SELINEXOR PLUS CYTARABINE AND IDARUBICIN IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
15 septembra, 2020 7:11 pmAuthor(s): Walter Fiedler, Joerg Chromik, Stefanie Amberg, et. al.: EHA Library. Fiedler W. Jun 15, 2019; 267463; S880 Abstract:...